Shares of Third Wave Technologies rose 8.4 percent for the five-day trading period ended Tuesday. The firm’s stock is up 17.7 percent since announcing on Dec. 5 that it had received the CE Mark for its HPV molecular diagnostic test, allowing it to sell the test throughout the European Union.
 
Qiagen led decliners for the week with a drop of 5.9 percent. Overall, 16 of the 21 stocks in the BCW Index lost value during the tracking period, and the Index closed down 1.1 percent.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.